Compare XBIT & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
| Metric | XBIT | NEN |
|---|---|---|
| Founded | 2005 | 1977 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 209.2M |
| IPO Year | 2015 | 1995 |
| Metric | XBIT | NEN |
|---|---|---|
| Price | $2.43 | $60.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 20.1K | 831.0 |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.71% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $89,196,544.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.68 |
| Revenue Growth | N/A | ★ 10.76 |
| 52 Week Low | $2.09 | $56.00 |
| 52 Week High | $3.61 | $75.00 |
| Indicator | XBIT | NEN |
|---|---|---|
| Relative Strength Index (RSI) | 48.22 | 54.51 |
| Support Level | $2.35 | $57.00 |
| Resistance Level | $2.49 | $66.30 |
| Average True Range (ATR) | 0.06 | 0.66 |
| MACD | -0.01 | 0.24 |
| Stochastic Oscillator | 42.86 | 100.00 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.